CoChat
Sign Up
Cited by 468

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins

Martínez, Paula, Blasco, María A.·2011·Nature Reviews Cancer
DOI 10.1038/nrc3025
Open this paper in CoChat — free account

Abstract

Mammalian telomeres are formed by tandem repeats of the TTAGGG sequence, which are progressively lost with each round of cell division. Telomere protection requires a minimal length of TTAGGG repeats to allow the binding of shelterin, which prevents the activation of a DNA damage response (DDR) at chromosome ends. Telomere elongation is carried out by telomerase. Telomerase can also act as a transcriptional modulator of the Wnt-β-catenin signalling pathway and has RNA-dependent RNA polymerase activity. Dysfunctional telomeres can lead to either cancer or ageing pathologies depending on the integrity of the DDR. This Review discusses the role of telomeric proteins in cancer and ageing through modulating telomere length and protection, as well as regulating gene expression by binding to non-telomeric sites.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrc3025

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 59 references

Research works printed but not linked: 141

  1. Takai, H., Smogorzewska, A. & de Lange, T. DNA damage foci at dysfunctional telomeres. Curr. Biol. 13, 1549–1556 (2003). · DOI · Paper page
  2. Blasco, M. A. The epigenetic regulation of mammalian telomeres. Nature Rev. Genet. 8, 299–309 (2007). · DOI · Paper page
  3. Palm, W. & de Lange, T. How shelterin protects mammalian telomeres. Annu. Rev. Genet. 42, 301–334 (2008). · DOI · Paper page
  4. Blackburn, E. H. Switching and signaling at the telomere. Cell 106, 661–673 (2001). · DOI
  5. de Lange, T. How telomeres solve the end-protection problem. Science 326, 948–952 (2009). · DOI · Paper page
  6. Cosme-Blanco, W. & Chang, S. Dual roles of telomere dysfunction in initiation and suppression of tumorigenesis. Exp. Cell Res. 314, 1973–1979 (2008). · DOI
  7. Feldser, D. M. & Greider, C. W. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 11, 461–469 (2007). · DOI · Paper page
  8. Samper, E. et al. Long-term repopulating ability of telomerase-deficient murine hematopoietic stem cells. Blood 99, 2767–2775 (2002). · DOI
  9. Cayuela, M. L., Flores, J. M. & Blasco, M. A. The telomerase RNA component Terc is required for the tumour-promoting effects of Tert overexpression. EMBO Rep. 6, 268–274 (2005). · DOI
  10. Flores, I., Cayuela, M. L. & Blasco, M. A. Effects of telomerase and telomere length on epidermal stem cell behavior. Science 309, 1253–1256 (2005). · DOI · Paper page
  11. Gonzalez-Suarez, E. et al. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 20, 2619–2630 (2001). · DOI · Paper page
  12. Smogorzewska, A. & de Lange, T. Regulation of telomerase by telomeric proteins. Annu. Rev. Biochem. 73, 177–208 (2004). · DOI
  13. Chiang, Y. J., Kim, S. H., Tessarollo, L., Campisi, J. & Hodes, R. J. Telomere-associated protein TIN2 is essential for early embryonic development through a telomerase-independent pathway. Mol. Cell Biol. 24, 6631–6634 (2004). · DOI
  14. Hockemeyer, D., Daniels, J. P., Takai, H. & de Lange, T. Recent expansion of the telomeric complex in rodents: Two distinct POT1 proteins protect mouse telomeres. Cell 126, 63–77 (2006). · DOI · Paper page
  15. Karlseder, J. et al. Targeted deletion reveals an essential function for the telomere length regulator Trf1. Mol. Cell Biol. 23, 6533–6541 (2003). · DOI
  16. Kibe, T., Osawa, G. A., Keegan, C. E. & de Lange, T. Telomere protection by TPP1 is mediated by POT1a and POT1b. Mol. Cell Biol. 30, 1059–1066 (2010). · DOI
  17. Lazzerini Denchi, E., Celli, G. & de Lange, T. Hepatocytes with extensive telomere deprotection and fusion remain viable and regenerate liver mass through endoreduplication. Genes Dev. 20, 2648–2653 (2006). · DOI · Paper page
  18. Martinez, P. & Blasco, M. A. Role of shelterin in cancer and aging. Aging Cell 9, 653–666 (2010). · DOI · Paper page
  19. Martinez, P. et al. Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice. Genes Dev. 23, 2060–2075 (2009). This paper describes the effect of TRF1 deletion in MEFs and in the stratified epithelia of mice. It demonstrates that TRF1 is required for telomere capping and for proper telomere replication. · DOI
  20. Else, T. et al. Genetic p53 deficiency partially rescues the adrenocortical dysplasia phenotype at the expense of increased tumorigenesis. Cancer Cell 15, 465–476 (2009). This paper shows that p53 loss rescues the adrenocortical dysplasia phenotype in mice with a hypomorphic TPP1 mutation but triggers the incidence of carcinomas. It proves the in vivo role of telomere vulnerability in tumorigenesis. · DOI · Paper page
  21. Tejera, A. et al. TPP1 is required for TERT recruitment, telomere elongation during nuclear reprogramming, and normal skin development in mice. Dev. Cell 18, 691–702 (2010). This papers shows that TPP1 is involved in both end protection and telomerase regulation in vivo . It highlights the relevance of telomerase activity in highly proliferative tissues and in the reprogramming of cells to induce pluripotency. · DOI
  22. Blasco, M. A. Telomeres and human disease: ageing, cancer and beyond. Nature Rev. Genet. 6, 611–622 (2005). · DOI · Paper page
  23. Munoz, P., Blanco, R., Flores, J. M. & Blasco, M. A. XPF nuclease-dependent telomere loss and increased DNA damage in mice overexpressing TRF2 result in premature aging and cancer. Nature Genet. 37, 1063–1071 (2005). This paper shows that overexpression of TRF2 results in a severe phenotype in the skin in response to light recapitulating the phenotypes observed in xeroderma pigmentosum. These observations provide in vivo links between the NER pathway and telomere maintenance mechanisms. · DOI
  24. Poncet, D. et al. Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood 111, 2388–2391 (2008). · DOI
  25. Abreu, E. et al. TIN2-tethered TPP1 recruits human telomerase to telomeres in vivo. Mol. Cell Biol. 30, 2971–2982 (2010). This paper demonstrates that TIN2-anchored TPP1 has a role in telomerase recruitment to telomeres in human cells. It also shows that telomerase recruitment does not depend on POT1 or on interaction of the shelterin complex with the single-stranded region of the telomeres. · DOI
  26. Martinez, P. et al. Mammalian Rap1 controls telomere function and gene expression through binding to telomeric and extratelomeric sites. Nature Cell Biol. 12, 768–780 (2010). This paper demonstrates that RAP1 binds to both telomeres and to extratelomeric genomic sites. It also shows that RAP1 is involved in subtelomeric gene silencing and exerts a transcriptional regulatory function. · DOI
  27. Teo, H. et al. Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-dependent gene expression. Nature Cell Biol. 12, 758–767 (2010). This paper identifies a cytoplasmatic role of RAP1 and provides a molecular mechanism by which RAP1 exerts a crucial function in the NF-κB signalling pathway, independently of its telomeric function. · DOI
  28. Zaug, A. J., Podell, E. R., Nandakumar, J. & Cech, T. R. Functional interaction between telomere protein TPP1 and telomerase. Genes Dev. 24, 613–622 (2010). This paper shows that POT1–TPP1 binding to telomeres activates telomerase repeat addition processivity and that this activation is dependent on specific interaction with the TEN domain of TERT. · DOI
  29. Olovnikov, A. M. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J. Theor. Biol. 41, 181–190 (1973). · DOI
  30. Greider, C. W. & Blackburn, E. H. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43, 405–413 (1985). · DOI · Paper page
  31. Liu, L. et al. Telomere lengthening early in development. Nature Cell Biol. 9, 1436–1441 (2007). · DOI
  32. Marion, R. M. et al. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell 4, 141–154 (2009). This paper demonstrates that telomeres are elongated in a telomerase-dependent manner and acquire the epigenetic markers of ES cells during nuclear reprogramming. That initial telomere length in parental cells is a determinant for the iPS generation efficiency is also shown. · DOI · Paper page
  33. Collado, M., Blasco, M. A. & Serrano, M. Cellular senescence in cancer and aging. Cell 130, 223–233 (2007). · DOI · Paper page
  34. Mitchell, J. R., Wood, E. & Collins, K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402, 551–555 (1999). · DOI · Paper page
  35. Schoeftner, S. & Blasco, M. A. A 'higher order' of telomere regulation: telomere heterochromatin and telomeric RNAs. EMBO J. 28, 2323–2336 (2009). · DOI
  36. Benetti, R. et al. Suv4–20h deficiency results in telomere elongation and derepression of telomere recombination. J. Cell Biol. 178, 925–936 (2007). · DOI
  37. Garcia-Cao, M., O'Sullivan, R., Peters, A. H., Jenuwein, T. & Blasco, M. A. Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nature Genet. 36, 94–99 (2004). · DOI
  38. Gonzalo, S. et al. DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nature Cell Biol. 8, 416–424 (2006). · DOI · Paper page
  39. Benetti, R. et al. A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nature Struct. Mol. Biol. 15, 268–279 (2008). · DOI
  40. Azzalin, C. M., Reichenbach, P., Khoriauli, L., Giulotto, E. & Lingner, J. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 318, 798–801 (2007). · DOI
  41. Schoeftner, S. & Blasco, M. A. Developmentally regulated transcription of mammalian telomeres by DNA-dependent RNA polymerase II. Nature Cell Biol. 10, 228–236 (2008). · DOI
  42. Court, R., Chapman, L., Fairall, L. & Rhodes, D. How the human telomeric proteins TRF1 and TRF2 recognize telomeric DNA: a view from high-resolution crystal structures. EMBO Rep. 6, 39–45 (2005). · DOI
  43. Bianchi, A. et al. TRF1 binds a bipartite telomeric site with extreme spatial flexibility. EMBO J. 18, 5735–5744 (1999). · DOI · Paper page
  44. Lei, M., Podell, E. R. & Cech, T. R. Structure of human POT1 bound to telomeric single-stranded DNA provides a model for chromosome end-protection. Nature Struct. Mol. Biol. 11, 1223–1229 (2004). · DOI
  45. Baumann, P. & Cech, T. R. Pot1, the putative telomere end-binding protein in fission yeast and humans. Science 292, 1171–1175 (2001). · DOI · Paper page
  46. Loayza, D. & De Lange, T. POT1 as a terminal transducer of TRF1 telomere length control. Nature 423, 1013–1018 (2003). · DOI
  47. He, H. et al. POT1b protects telomeres from end-to-end chromosomal fusions and aberrant homologous recombination. EMBO J. 25, 5180–5190 (2006). · DOI
  48. Kim, S. H. et al. TIN2 mediates functions of TRF2 at human telomeres. J. Biol. Chem. 279, 43799–43804 (2004). · DOI
  49. Chen, Y. et al. A shared docking motif in TRF1 and TRF2 used for differential recruitment of telomeric proteins. Science 319, 1092–1096 (2008). · DOI
  50. Chen, L. Y., Liu, D. & Songyang, Z. Telomere maintenance through spatial control of telomeric proteins. Mol. Cell Biol. 27, 5898–5909 (2007). · DOI
  51. Xin, H. et al. TPP1 is a homologue of ciliate TEBP-beta and interacts with POT1 to recruit telomerase. Nature 445, 559–562 (2007). · DOI
  52. Li, B. & de Lange, T. Rap1 affects the length and heterogeneity of human telomeres. Mol. Biol. Cell 14, 5060–5068 (2003). · DOI
  53. Li, B., Oestreich, S. & de Lange, T. Identification of human Rap1: implications for telomere evolution. Cell 101, 471–483 (2000). · DOI
  54. Sfeir, A., Kabir, S., van Overbeek, M., Celli, G. B. & de Lange, T. Loss of Rap1 induces telomere recombination in the absence of NHEJ or a DNA damage signal. Science 327, 1657–1661 (2010). This paper describes a crucial role for RAP1 in the inhibition of homology-directed repair at telomeres. RAP1 is shown to be dispensable for TRF2 function, repression of ATM signalling and the NHEJ pathway. · DOI
  55. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000). · DOI · Paper page
  56. Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352–1355 (2008). · DOI · Paper page
  57. Tsantoulis, P. K. et al. Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study. Oncogene 27, 3256–3264 (2008). · DOI
  58. Engelhardt, M., Drullinsky, P., Guillem, J. & Moore, M. A. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin. Cancer Res. 3, 1931–1941 (1997).
  59. Engelhardt, M. et al. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma. Clin. Cancer Res. 3, 1849–1857 (1997).
  60. Odagiri, E. et al. Reduction of telomeric length and c-erbB-2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters. Cancer 73, 2978–2984 (1994). · DOI
  61. Meeker, A. K. et al. Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am. J. Pathol. 164, 925–935 (2004). · DOI · Paper page
  62. Meeker, A. K. et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin. Cancer Res. 10, 3317–3326 (2004). · DOI · Paper page
  63. Artandi, S. E. et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406, 641–645 (2000). This paper was the first to demonstrate that critically short telomeres in a Trp53 -deficient genetic background lead to the development of epithelial cancers. It highlights that genomic instability that is induced by telomere dysfunction induces tumorigenesis and establishes a key role for p53 in the cellular response to telomere dysfunction in vivo. · DOI · Paper page
  64. Denchi, E. L. Give me a break: how telomeres suppress the DNA damage response. DNA Repair (Amst) 8, 1118–1126 (2009). · DOI
  65. Rai, R. et al. The function of classical and alternative non-homologous end-joining pathways in the fusion of dysfunctional telomeres. EMBO J. 29, 2598–2610 (2010). · DOI
  66. Espejel, S. et al. Mammalian Ku86 mediates chromosomal fusions and apoptosis caused by critically short telomeres. EMBO J. 21, 2207–2219 (2002). · DOI
  67. Maser, R. S. et al. DNA-dependent protein kinase catalytic subunit is not required for dysfunctional telomere fusion and checkpoint response in the telomerase-deficient mouse. Mol. Cell Biol. 27, 2253–2265 (2007). · DOI
  68. Murnane, J. P. Telomere loss as a mechanism for chromosome instability in human cancer. Cancer Res. 70, 4255–4259 (2010). · DOI
  69. Gilson, E. & Geli, V. How telomeres are replicated. Nature Rev. Mol. Cell Biol. 8, 825–838 (2007). · DOI
  70. Oganesian, L. & Bryan, T. M. Physiological relevance of telomeric G-quadruplex formation: a potential drug target. Bioessays 29, 155–165 (2007). · DOI
  71. Cacchione, S., Cerone, M. A. & Savino, M. In vitro low propensity to form nucleosomes of four telomeric sequences. FEBS Lett. 400, 37–41 (1997). · DOI
  72. Verdun, R. E. & Karlseder, J. The DNA damage machinery and homologous recombination pathway act consecutively to protect human telomeres. Cell 127, 709–720 (2006). · DOI
  73. McNees, C. J. et al. ATR suppresses telomere fragility and recombination but is dispensable for elongation of short telomeres by telomerase. J. Cell Biol. 188, 639–652 (2010). · DOI
  74. Casper, A. M., Durkin, S. G., Arlt, M. F. & Glover, T. W. Chromosomal instability at common fragile sites in Seckel syndrome. Am. J. Hum. Genet. 75, 654–660 (2004). · DOI
  75. Murga, M. et al. A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nature Genet. 41, 891–898 (2009). · DOI · Paper page
  76. Okamoto, K., Iwano, T., Tachibana, M. & Shinkai, Y. Distinct roles of TRF1 in the regulation of telomere structure and lengthening. J. Biol. Chem. 283, 23981–23988 (2008). · DOI
  77. Else, T. et al. Tpp1/Acd maintains genomic stability through a complex role in telomere protection. Chromosome Res. 15, 1001–1013 (2007). · DOI
  78. Keegan, C. E. et al. Urogenital and caudal dysgenesis in adrenocortical dysplasia (acd) mice is caused by a splicing mutation in a novel telomeric regulator. Hum. Mol. Genet. 14, 113–123 (2005). · DOI · Paper page
  79. Carroll, K. A. & Ly, H. Telomere dysfunction in human diseases: the long and short of it! Int. J. Clin. Exp. Pathol. 2, 528–543 (2009).
  80. Henle, E. S. et al. Sequence-specific DNA cleavage by Fe2+-mediated fenton reactions has possible biological implications. J. Biol. Chem. 274, 962–971 (1999). · DOI
  81. Oikawa, S., Tada-Oikawa, S. & Kawanishi, S. Site-specific DNA damage at the GGG sequence by UVA involves acceleration of telomere shortening. Biochemistry 40, 4763–4768 (2001). · DOI
  82. Ayouaz, A., Raynaud, C., Heride, C., Revaud, D. & Sabatier, L. Telomeres: hallmarks of radiosensitivity. Biochimie 90, 60–72 (2008). · DOI
  83. Sitte, N., Saretzki, G. & von Zglinicki, T. Accelerated telomere shortening in fibroblasts after extended periods of confluency. Free Radic Biol. Med. 24, 885–893 (1998). · DOI
  84. Munoz, P. et al. TRF1 controls telomere length and mitotic fidelity in epithelial homeostasis. Mol. Cell Biol. 29, 1608–1625 (2009). · DOI
  85. Zhu, X. D. et al. ERCC1/XPF removes the 3′ overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol. Cell 12, 1489–1498 (2003). · DOI
  86. Munoz, P., Blanco, R. & Blasco, M. A. Role of the TRF2 telomeric protein in cancer and ageing. Cell Cycle 5, 718–721 (2006). · DOI
  87. Sands, A. T., Abuin, A., Sanchez, A., Conti, C. J. & Bradley, A. High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC. Nature 377, 162–165 (1995). · DOI
  88. Nakane, H. et al. High incidence of ultraviolet-B-or chemical-carcinogen-induced skin tumours in mice lacking the xeroderma pigmentosum group A gene. Nature 377, 165–168 (1995). · DOI
  89. Rajagopalan, H. & Lengauer, C. Aneuploidy and cancer. Nature 432, 338–341 (2004). · DOI
  90. Sen, S. Aneuploidy and cancer. Curr. Opin. Oncol. 12, 82–88 (2000). · DOI
  91. Sotillo, R. et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11, 9–23 (2007). · DOI · Paper page
  92. Weaver, B. A., Silk, A. D., Montagna, C., Verdier-Pinard, P. & Cleveland, D. W. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11, 25–36 (2007). · DOI · Paper page
  93. Davoli, T., Denchi, E. L. & de Lange, T. Persistent telomere damage induces bypass of mitosis and tetraploidy. Cell 141, 81–93 (2010). This paper provides a molecular mechanism underlying tetraploidization as a consequence of persistent telomere dysfunction. A prolonged DNA damage signal in a TP53 -deficient background and its consequent activation of ATM and ATR results in the inhibition of CDK1–cyclin B, cells bypass mitosis and enter a second S phase becoming tetraploid. A molecular explanation about the high incidence of aneuploid cells in tumours is given. · DOI · Paper page
  94. Pantic, M. et al. Telomere dysfunction and loss of p53 cooperate in defective mitotic segregation of chromosomes in cancer cells. Oncogene 25, 4413–4420 (2006). · DOI
  95. Toledo, L. I., Murga, M., Gutierrez-Martinez, P., Soria, R. & Fernandez-Capetillo, O. ATR signaling can drive cells into senescence in the absence of DNA breaks. Genes Dev. 22, 297–302 (2008). · DOI · Paper page
  96. Denchi, E. L. & de Lange, T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 448, 1068–1071 (2007). · DOI · Paper page
  97. Hockemeyer, D., Palm, W., Wang, R. C., Couto, S. S. & de Lange, T. Engineered telomere degradation models dyskeratosis congenita. Genes Dev. 22, 1773–1785 (2008). This paper shows that mice lacking Pot1b in combination with reduced telomerase activity develop phenotypes that recapitulate those observed in patients with dyskeratosis congenita such as hyperpigmentation and fatal bone marrow failure. It highlights the idea that this disease is caused by telomere dysfunction. · DOI
  98. He, H. et al. Pot1b deletion and telomerase haploinsufficiency in mice initiate an ATR-dependent DNA damage response and elicit phenotypes resembling dyskeratosis congenita. Mol. Cell Biol. 29, 229–240 (2009). · DOI
  99. Shay, J. W. & Wright, W. E. Telomerase therapeutics for cancer: challenges and new directions. Nature Rev. Drug Discov. 5, 577–584 (2006). · DOI
  100. Shore, D. & Nasmyth, K. Purification and cloning of a DNA binding protein from yeast that binds to both silencer and activator elements. Cell 51, 721–732 (1987). · DOI
  101. Kyrion, G., Liu, K., Liu, C. & Lustig, A. J. RAP1 and telomere structure regulate telomere position effects in Saccharomyces cerevisiae. Genes Dev. 7, 1146–1159 (1993). · DOI
  102. Hecht, A., Laroche, T., Strahl-Bolsinger, S., Gasser, S. M. & Grunstein, M. Histone H3 and H4 N-termini interact with SIR3 and SIR4 proteins: a molecular model for the formation of heterochromatin in yeast. Cell 80, 583–592 (1995). · DOI
  103. Tanny, J. C., Dowd, G. J., Huang, J., Hilz, H. & Moazed, D. An enzymatic activity in the yeast Sir2 protein that is essential for gene silencing. Cell 99, 735–745 (1999). · DOI
  104. Carmen, A. A., Milne, L. & Grunstein, M. Acetylation of the yeast histone H4 N. terminus regulates its binding to heterochromatin protein SIR3. J. Biol. Chem. 277, 4778–4781 (2002). · DOI
  105. Buchman, A. R., Kimmerly, W. J., Rine, J. & Kornberg, R. D. Two DNA-binding factors recognize specific sequences at silencers, upstream activating sequences, autonomously replicating sequences, and telomeres in Saccharomyces cerevisiae. Mol. Cell Biol. 8, 210–225 (1988). · DOI
  106. Capieaux, E., Vignais, M. L., Sentenac, A. & Goffeau, A. The yeast H+-ATPase gene is controlled by the promoter binding factor TUF. J. Biol. Chem. 264, 7437–7446 (1989). · DOI
  107. Yang, X., Figueiredo, L. M., Espinal, A., Okubo, E. & Li, B. RAP1 is essential for silencing telomeric variant surface glycoprotein genes in Trypanosoma brucei. Cell 137, 99–109 (2009). · DOI
  108. Hanaoka, S. et al. NMR structure of the hRap1 Myb motif reveals a canonical three-helix bundle lacking the positive surface charge typical of Myb DNA-binding domains. J. Mol. Biol. 312, 167–175 (2001). · DOI
  109. Basseres, D. S. & Baldwin, A. S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25, 6817–6830 (2006). · DOI
  110. Akiyama, M. et al. Nuclear factor-κB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. 63, 18–21 (2003).
  111. Artandi, S. E. et al. Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc. Natl Acad. Sci. USA 99, 8191–8196 (2002). · DOI · Paper page
  112. Gonzalez-Suarez, E., Flores, J. M. & Blasco, M. A. Cooperation between p53 mutation and high telomerase transgenic expression in spontaneous cancer development. Mol. Cell Biol. 22, 7291–7301 (2002). · DOI
  113. Canela, A., Martin-Caballero, J., Flores, J. M. & Blasco, M. A. Constitutive expression of tert in thymocytes leads to increased incidence and dissemination of T-cell lymphoma in Lck-Tert mice. Mol. Cell Biol. 24, 4275–4293 (2004). · DOI · Paper page
  114. Shete, S. et al. Genome-wide association study identifies five susceptibility loci for glioma. Nature Genet. 41, 899–904 (2009). · DOI
  115. Petersen, G. M. et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature Genet. 42, 224–228 (2010). · DOI
  116. McKay, J. D. et al. Lung cancer susceptibility locus at 5p15.33. Nature Genet. 40, 1404–1406 (2008). · DOI
  117. Rafnar, T. et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nature Genet. 41, 221–227 (2009). · DOI
  118. Wang, Y. et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nature Genet. 40, 1407–1409 (2008). · DOI
  119. Zhang, A. et al. Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int. J. Cancer 101, 427–433 (2002). · DOI
  120. Kang, J. U., Koo, S. H., Kwon, K. C., Park, J. W. & Kim, J. M. Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet. Cytogenet. 182, 1–11 (2008). · DOI
  121. Hao, L. Y. et al. Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 123, 1121–1131 (2005). · DOI · Paper page
  122. Reya, T. & Clevers, H. Wnt signalling in stem cells and cancer. Nature 434, 843–850 (2005). · DOI · Paper page
  123. Cong, Y. & Shay, J. W. Actions of human telomerase beyond telomeres. Cell Res. 18, 725–732 (2008). · DOI
  124. Ridanpaa, M. et al. Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. Cell 104, 195–203 (2001). · DOI
  125. Santos, J. H., Meyer, J. N., Skorvaga, M., Annab, L. A. & Van Houten, B. Mitochondrial hTERT exacerbates free-radical-mediated mtDNA damage. Aging Cell 3, 399–411 (2004). · DOI
  126. Santos, J. H., Meyer, J. N. & Van Houten, B. Mitochondrial localization of telomerase as a determinant for hydrogen peroxide-induced mitochondrial DNA damage and apoptosis. Hum. Mol. Genet. 15, 1757–1768 (2006). · DOI
  127. Haendeler, J. et al. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. Circ. Res. 94, 768–775 (2004). · DOI
  128. Zhang, P., Chan, S. L., Fu, W., Mendoza, M. & Mattson, M. P. TERT suppresses apoptotis at a premitochondrial step by a mechanism requiring reverse transcriptase activity and 14-3-3 protein-binding ability. FASEB J. 17, 767–769 (2003). · DOI
  129. Vidal-Cardenas, S. L. & Greider, C. W. Comparing effects of mTR and mTERT deletion on gene expression and DNA damage response: a critical examination of telomere length maintenance-independent roles of telomerase. Nucleic Acids Res. 38, 60–71 (2010). · DOI
  130. Erdmann, N. & Harrington, L. A. No attenuation of the ATM-dependent DNA damage response in murine telomerase-deficient cells. DNA Repair (Amst) 8, 347–353 (2009). · DOI
  131. Zhang, J. Z. Overexpression analysis of plant transcription factors. Curr. Opin. Plant Biol. 6, 30–440 (2003). · DOI
  132. Barolo, S. Transgenic Wnt/TCF pathway reporters: all you need is Lef? Oncogene 25, 7505–7511 (2006). · DOI
  133. Cortez-Gonzalez, X. & Zanetti, M. Telomerase immunity from bench to bedside: round one. J. Transl. Med. 5, 12 (2007). · DOI
  134. Latrick, C. M. & Cech, T. R. POT1-TPP1 enhances telomerase processivity by slowing primer dissociation and aiding translocation. EMBO J. 29, 924–933 (2010). · DOI
  135. Savage, S. A. et al. Genetic variation in telomeric repeat binding factors 1 and 2 in aplastic anemia. Exp. Hematol. 34, 664–671 (2006). · DOI · Paper page
  136. Blasco, M. A. & Hahn, W. C. Evolving views of telomerase and cancer. Trends Cell Biol. 13, 289–294 (2003). · DOI · Paper page
  137. Artandi, S. E. & DePinho, R. A. A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr. Opin. Genet. Dev. 10, 39–46 (2000). · DOI · Paper page
  138. Begus-Nahrmann, Y. et al. p53 deletion impairs clearance of chromosomal-instable stem cells in aging telomere-dysfunctional mice. Nature Genet. 41, 1138–1143 (2009). · DOI · Paper page
  139. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007). · DOI · Paper page
  140. Tsangaris, E. et al. Ataxia and pancytopenia caused by a mutation in TINF2. Hum. Genet. 124, 507–513 (2008). · DOI
  141. Ye, J. Z. et al. TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on telomeres. J. Biol. Chem. 279, 47264–47271 (2004). · DOI

Cited by

Sorted by citations

See all 468

Metadata

Authors
Martínez, P., & Blasco, M. A.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2011-02-24
Volume
11
Issue
3
Pages
161-176
ISSN
  • 1474-175X
  • 1474-1768
DOI
10.1038/nrc3025
Cited by
468
References
59
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review